BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36001945)

  • 1. A Retrospective Chart Review of 809 Patients with Physician-Diagnosed Essential Thrombocythemia Receiving Cytoreductive Therapy in US Community Oncology Practices.
    Yu J; Paranagama D; Hanna B; Tang J; Chojecki A
    Acta Haematol; 2023; 146(1):26-36. PubMed ID: 36001945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
    Tefferi A; Barbui T
    Am J Hematol; 2017 Jan; 92(1):94-108. PubMed ID: 27991718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Essential Thrombocythemia with Anagrelide Is Associated with an Increased Risk of Worsened Kidney Function.
    Kwiatkowski J; Kuliszkiewicz-Janus M; Rymer W; Jaźwiec B; Małecki R
    Pharmacology; 2021; 106(5-6):316-322. PubMed ID: 33691325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
    Tefferi A; Barbui T
    Am J Hematol; 2019 Jan; 94(1):133-143. PubMed ID: 30281843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice.
    Tefferi A; Barbui T
    Mayo Clin Proc; 2015 Sep; 90(9):1283-93. PubMed ID: 26355403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma levels of angiogenic factors and circulating endothelial cells in essential thrombocythemia: correlation with cytoreductive therapy and JAK2-V617F mutational status.
    Treliński J; Wierzbowska A; Krawczyńska A; Sakowicz A; Pietrucha T; Smolewski P; Robak T; Chojnowski K
    Leuk Lymphoma; 2010 Sep; 51(9):1727-33. PubMed ID: 20615083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.
    Tefferi A; Barbui T
    Am J Hematol; 2020 Dec; 95(12):1599-1613. PubMed ID: 32974939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy.
    Girodon F; Schaeffer C; Cleyrat C; Mounier M; Lafont I; Santos FD; Duval A; Maynadié M; Hermouet S
    Haematologica; 2008 Nov; 93(11):1723-7. PubMed ID: 18728027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contemporary management of essential thrombocythemia in children.
    Randi ML; Bertozzi I; Putti MC
    Expert Rev Hematol; 2019 May; 12(5):367-373. PubMed ID: 30925843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Essential differences in clinical and bone marrow features in BCR/ABL-positive thrombocythemia compared to thrombocythemia in the BCR/ABL-negative myeloproliferative neoplasms essential thrombocythemia and polycythemia vera.
    Michiels JJ; Pich A; De Raeve H; Gadisseur A
    Acta Haematol; 2015; 133(1):52-5. PubMed ID: 25116159
    [No Abstract]   [Full Text] [Related]  

  • 11. Essential thrombocythemia: scientific advances and current practice.
    Tefferi A
    Curr Opin Hematol; 2006 Mar; 13(2):93-8. PubMed ID: 16456375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
    Tefferi A; Barbui T
    Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK2 V617F-positive latent essential thrombocythemia and splanchnic vein thrombosis: the role of bone marrow biopsy for the diagnosis of myeloproliferative disease.
    Allegra A; Alonci A; Penna G; D'Angelo A; Rizzotti P; Granata A; Musolino C
    Acta Haematol; 2009; 121(4):218-20. PubMed ID: 19478480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CAL2 monoclonal antibody is a rapid and sensitive assay for the detection of calreticulin mutations in essential thrombocythemia patients.
    Bonifacio M; Montemezzi R; Parisi A; De Matteis G; Bertorelle R; Scaffidi L; Candiotto C; Lippi G; Zamò A; Chilosi M; Pizzolo G; Scarpa A; Krampera M
    Ann Hematol; 2019 Oct; 98(10):2339-2346. PubMed ID: 31250082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impaired apoptosis of megakaryocytes and bone marrow mononuclear cells in essential thrombocythemia: correlation with JAK2V617F mutational status and cytoreductive therapy.
    Treliński J; Chojnowski K; Cebula-Obrzut B; Smolewski P
    Med Oncol; 2012 Dec; 29(4):2388-95. PubMed ID: 22418850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and histological characteristics of livedo racemosa in essential thrombocythemia: A report of two cases and review of the published works.
    Inoue S; Okiyama N; Okune M; Shiraki N; Kessoku R; Fujimoto M
    J Dermatol; 2017 Jan; 44(1):84-87. PubMed ID: 27570091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytoreductive treatment in patients with CALR-mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia.
    Alvarez-Larrán A; Angona A; Andrade-Campos M; Soledad Noya M; Teresa Gómez-Casares M; Cuevas B; Caballero G; García-Hernández C; García-Gutiérrez V; Palomino A; Ferrer-Marín F; Isabel Mata-Vázquez M; Moretó A; Magro E; Murillo I; Manuel Alonso-Domínguez J; María Guerra J; Guerrero L; María Raya J; Pérez-Encinas M; Carreño-Tarragona G; Fox L; Pastor-Galán I; Bellosillo B; Hernández-Boluda JC;
    Br J Haematol; 2021 Mar; 192(6):988-996. PubMed ID: 32745264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK2, MPL, and CALR mutations in Chinese Han patients with essential thrombocythemia.
    Wang J; Zhang B; Chen B; Zhou RF; Zhang QG; Li J; Yang YG; Zhou M; Shao XY; Xu Y; Xu XH; Ouyang J; Xu J; Ye Q
    Hematology; 2017 Apr; 22(3):145-148. PubMed ID: 27875935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation.
    Huang BT; Zeng QC; Zhao WH; Li BS; Chen RL
    Leuk Res; 2014 Oct; 38(10):1177-83. PubMed ID: 25069759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.